Literature DB >> 10935539

Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging.

R Yu1, S G Ren, G A Horwitz, Z Wang, S Melmed.   

Abstract

The pituitary transforming gene, PTTG, is abundantly expressed in endocrine neoplasms. PTTG has recently been recognized as a mammalian securin based on its biochemical homology to Pds1p. PTTG expression and intracellular localization were therefore studied during the cell cycle in human placental JEG-3 cells. PTTG mRNA and protein expressions were low at the G1/S border, gradually increased during S phase, and peaked at G2/M, but PTTG levels were attenuated as cells entered G1. In interphase cells, wild-type PTTG, an epitope-tagged PTTG, and a PTTG-EGFP conjugate all localized to both the nucleus and cytoplasm, but in mitotic cells, PTTG was not observed in the chromosome region. PTTG-EGFP colocalized with mitotic spindles in early mitosis and was degraded in anaphase. Intracellular fates of PTTG-EGFP and a conjugate of EGFP and a mutant inactivated PTTG devoid of an SH3-binding domain were observed by real-time visualization of the EGFP conjugates in live cells. The same cells were continuously observed as they progressed from G1/S border to S, G2/M, and G1. Most cells (67%) expressing PTTG-EGFP died by apoptosis, and few cells (4%) expressing PTTG-EGFP divided, whereas those expressing mutant PTTG-EGFP divided. PTTG-EGFP, as well as the mutant PTTG-EGFP, disappeared after cells divided. The results show that PTTG expression and localization are cell cycle-dependent and demonstrate that PTTG regulates endocrine tumor cell division and survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935539     DOI: 10.1210/mend.14.8.0501

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  30 in total

1.  MiRNA-494 inhibits metastasis of cervical cancer through Pttg1.

Authors:  Bing Chen; Zhaohui Hou; Chundong Li; Ying Tong
Journal:  Tumour Biol       Date:  2015-04-16

2.  Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression.

Authors:  Zhen-Zhong Feng; Jia-Wei Chen; Zhao-Rui Yang; Guang-Zhong Lu; Zhao-Gen Cai
Journal:  Med Oncol       Date:  2010-12-22       Impact factor: 3.064

3.  Functional role of estrogen in pituitary tumor pathogenesis.

Authors:  Anthony P Heaney; Manory Fernando; Shlomo Melmed
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 4.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

5.  MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1.

Authors:  Tongle Zhi; Kuan Jiang; Xiupeng Xu; Tianfu Yu; Weining Wu; Er Nie; Xu Zhou; Xin Jin; Junxia Zhang; Yingyi Wang; Ning Liu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  Pituitary tumor-transforming gene 1 enhances metastases of cervical cancer cells through miR-3666-regulated ZEB1.

Authors:  Lin Li; Li-Ying Han; Ming Yu; Qi Zhou; Jian-Cheng Xu; Ping Li
Journal:  Tumour Biol       Date:  2015-09-17

Review 7.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

8.  Diminished pancreatic beta-cell mass in securin-null mice is caused by beta-cell apoptosis and senescence.

Authors:  Vera Chesnokova; Chris Wong; Svetlana Zonis; Anna Gruszka; Kolja Wawrowsky; Song-Guang Ren; Anat Benshlomo; Run Yu
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736

9.  Signaling pathway networks mined from human pituitary adenoma proteomics data.

Authors:  Xianquan Zhan; Dominic M Desiderio
Journal:  BMC Med Genomics       Date:  2010-04-28       Impact factor: 3.063

10.  Securin promotes the identification of favourable outcome in invasive breast cancer.

Authors:  K Talvinen; H Karra; S Hurme; M Nykänen; A Nieminen; J Anttinen; T Kuopio; P Kronqvist
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.